Literature DB >> 207650

Lysis of RSV-transformed Japanese quail cells by a factor from normal quail serum.

Y Yoshikawa, K Yamanouchi, M Hishiyama, K Kobune.   

Abstract

Normal sera of Japanese quails caused lysis of tumor cells from a Rous sarcoma virus (RSV)-induced quail tumor (QT cells). Other tumor cell lines, including RSV-transformed quail embryo cells and methylcholanthrene-induced quail tumors, were not lysed. This naturally occurring cytolytic factor (NCLF) was sensitive to heating at 56 degrees C, zymosan, and inulin, and it required magnesium but not calcium for the expression of its activity. These results suggested that NCLF activity was mediated by complement activated through an alternative pathway. This possible complement activation occurred in the absence of specific antibodies to the target cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 207650     DOI: 10.1002/ijc.2910210518

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Ontogeny of the third component of complement of Japanese quails.

Authors:  C Kai; Y Yoshikawa; K Yamanouchi; H Okada; S Morikawa
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

Review 2.  The complement system: its importance in the host response to viral infection.

Authors:  R L Hirsch
Journal:  Microbiol Rev       Date:  1982-03

3.  Lysis of horse red blood cells mediated by antibody-independent activation of the alternative pathway of chicken complement.

Authors:  H Ohta; Y Yoshikawa; C Kai; K Yamanouchi; H Okada
Journal:  Immunology       Date:  1984-07       Impact factor: 7.397

4.  Activation of chicken alternative complement pathway by fowlpox virus-infected cells.

Authors:  H Ohta; C Kai; Y Yoshikawa; K Yamanouchi
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

5.  Cytolysis of Sendai virus-infected guinea-pig cells by homologous complement.

Authors:  H Okada; H Tanaka; N Okada
Journal:  Immunology       Date:  1983-05       Impact factor: 7.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.